drugset / Trial / NCT01841359

Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

NCT01841359

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to determine whether pramlintide (Symlin) will help to reduce the frequency and severity of hypoglycemia in individuals who have had gastric bypass surgery.

Timeline

Start
2010-02-02
Primary completion
2016-07
Completion
2022-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Pramlintide Peptide

Indications